Walker JL - Search Results

1

Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study.

Chan JK, Tian C, Kesterson JP, Lin KY, Darcy K, Richardson MT, Kapp DS, Monk BJ, McNally L, Landrum L, Copeland L, Walker JL, Wenham RM, Phippen N, Spirtos NM, Tewari K, Shahin M, Berry L, Bell JG. Chan JK, et al. Among authors: walker jl. Gynecol Oncol. 2024 Feb;181:54-59. doi: 10.1016/j.ygyno.2023.12.009. Epub 2023 Dec 21. Gynecol Oncol. 2024. PMID: 38134754 Clinical Trial.

2

Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma.

Monk BJ, Cha DS, Walker JL, Burger RA, Ramsinghani NS, Manetta A, DiSaia PJ, Berman ML. Monk BJ, et al. Among authors: walker jl. Gynecol Oncol. 1994 Jul;54(1):4-9. doi: 10.1006/gyno.1994.1157. Gynecol Oncol. 1994. PMID: 8020837

3

Open interstitial brachytherapy for the treatment of local-regional recurrences of uterine corpus and cervix cancer after primary surgery.

Monk BJ, Walker JL, Tewari K, Ramsinghani NS, Nisar Syed AM, DiSaia PJ. Monk BJ, et al. Among authors: walker jl. Gynecol Oncol. 1994 Feb;52(2):222-8. doi: 10.1006/gyno.1994.1035. Gynecol Oncol. 1994. PMID: 8314143

4

Ovarian vein vs peripheral blood CA125 serum levels: a comparative study.

Podnos YD, Gamboa G, Kurosaki T, Buller R, Walker JL, Manetta A. Podnos YD, et al. Among authors: walker jl. Gynecol Oncol. 1997 Jul;66(1):71-4. doi: 10.1006/gyno.1997.4712. Gynecol Oncol. 1997. PMID: 9234924

5

A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. Rose PG, et al. Among authors: walker jl. Gynecol Oncol. 2000 Aug;78(2):212-6. doi: 10.1006/gyno.2000.5865. Gynecol Oncol. 2000. PMID: 10926805 Clinical Trial.

6

Analysis of FIGO Stage IIIc endometrial cancer patients.

McMeekin DS, Lashbrook D, Gold M, Johnson G, Walker JL, Mannel R. McMeekin DS, et al. Among authors: walker jl. Gynecol Oncol. 2001 May;81(2):273-8. doi: 10.1006/gyno.2001.6157. Gynecol Oncol. 2001. PMID: 11330962

7

Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?

Kamelle SA, Rutledge TL, Tillmanns TD, Gould NS, Cohn DE, Wright J, Herzog TJ, Rader JS, Gold MA, Johnson GA, Walker JL, Mannel RS, McMeekin DS. Kamelle SA, et al. Among authors: walker jl. Gynecol Oncol. 2004 Aug;94(2):249-55. doi: 10.1016/j.ygyno.2004.05.038. Gynecol Oncol. 2004. PMID: 15297159

8

A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?

Rutledge TL, Kamelle SA, Tillmanns TD, Gould NS, Wright JD, Cohn DE, Herzog TJ, Rader JS, Gold MA, Johnson GA, Walker JL, Mannel RS, McMeekin DS. Rutledge TL, et al. Among authors: walker jl. Gynecol Oncol. 2004 Oct;95(1):70-6. doi: 10.1016/j.ygyno.2004.07.027. Gynecol Oncol. 2004. PMID: 15385112

9

Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.

McMeekin DS, Tillmanns T, Chaudry T, Gold M, Johnson G, Walker J, Mannel R. McMeekin DS, et al. Gynecol Oncol. 2004 Oct;95(1):157-64. doi: 10.1016/j.ygyno.2004.07.008. Gynecol Oncol. 2004. PMID: 15385126

10

Carcinosarcoma of the ovary-a case series.

Rutledge TL, Gold MA, McMeekin DS, Huh WK, Powell MA, Lewin SN, Mutch DG, Johnson GA, Walker JL, Mannel RS. Rutledge TL, et al. Among authors: walker jl. Gynecol Oncol. 2006 Jan;100(1):128-32. doi: 10.1016/j.ygyno.2005.07.119. Epub 2005 Oct 5. Gynecol Oncol. 2006. PMID: 16213011

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

551 results

Search Page